EUVIMEDEUVIMED entdecken
Crossref

A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan‐Tissue Antigen‐Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy

Ling Zeng, Qian Shen, Lingyu Wei, Meng Jiang, Jing Liao, Yupeng Ren, Zixi Zhang, Hui Fan, Xinxiu Cao, Jinjin Chen iD, Jianxun Ding iD, Xuesi Chen

Advanced Materials · 2026

DOI: 10.1002/adma.202520594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Ling Zeng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Guangzhou Key Laboratory of Medical …. Hauptthemen laut MEDLINE: Antigen-Presenting Cells, Immunotherapy, Nanoparticles, RNA, Messenger. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Guangdong Province, Guangdong High-Level Youth Talent Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) vaccines have transformed cancer immunotherapy, yet delayed immune activation, multi‐dose requirements, and poor efficacy in immunosuppressive tumor microenvironments (TMEs) hinder current platforms. Here, a structurally stabilized lipopolymer nanoparticle (LPNP) platform is proposed for in situ mRNA vaccination targeting antigen‐presenting cells (APCs). Central to this system is a rationally engineered double‐branched lipopolymer, P6CIT, whose unique molecular architecture enhances hydrophobic microviscosity and intermolecular packing, increasing particle rigidity and preventing premature disassembly in biological fluids. This stabilization enhances circulation stability and promotes favorable biodistribution to tumor sites and lymphoid organs, resulting in a 6.9‐fold increase in the spleen and a 13.6‐fold increase in lymph nodes, key sites for adaptive immune activation. Upon intratumoral administration, the LPNP co‐delivers mRNAs encoding tumor antigens and IL‐12, synergistically reprogramming the TMEs and amplifying APC‐mediated T cell priming. In situ vaccination achieves a 42% complete response in a B16‐OVA melanoma model and outperforms ALC‐0315 LNPs in wild‐type B16F10 tumors. This work highlights chemical‐level structural optimization enabling potent, simplified mRNA immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigen-Presenting CellsImmunotherapyNanoparticlesRNA, MessengerPolymersCancer VaccinesAnimalsMiceTumor MicroenvironmentNanovaccinesMelanoma, ExperimentalInterleukin-12Cell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

antigen‐presenting cell targetingdurable immunityin situ mRNA vaccinelipopolymer nanoparticletumor microenvironment reprogramming

Substanzen

RNA, MessengerPolymersCancer VaccinesNanovaccinesInterleukin-12

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Guangzhou Key Laboratory of Medical Nanomaterials, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,…
  • Department of Pharmacy, the Second Affiliated Hospital, Hengyang, P. R. China.
  • School of Materials Science and Engineering, Hunan University of Science and Technology, Hengyang, P. R. China.
  • State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, P. R. China.

ORCID-Profile: Jinjin Chen, Jianxun Ding

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Planning Project of Guangdong Province
  • Guangdong High-Level Youth Talent Project
  • Grant from Guangzhou Science and Technology Bureau
  • Science and Technology Development Program of Jilin Province
  • Sun Yat-sen Clinical Scientist Program
  • Youth Innovationtion Association of Chinese Academy of Sciences

Zitieren

APA

Zeng, L., Shen, Q., Wei, L., Jiang, M., Liao, J., Ren, Y., Zhang, Z., Fan, H., Cao, X., Chen, J., Ding, J., & Chen, X. (2026). A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan‐Tissue Antigen‐Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202520594

Vancouver

Zeng L, Shen Q, Wei L, Jiang M, Liao J, Ren Y, et al. A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan‐Tissue Antigen‐Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202520594

BibTeX
@article{Zeng2026,
  author = {Zeng, Ling and Shen, Qian and Wei, Lingyu and Jiang, Meng and Liao, Jing and Ren, Yupeng and Zhang, Zixi and Fan, Hui and Cao, Xinxiu and Chen, Jinjin and Ding, Jianxun and Chen, Xuesi},
  title = {A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan‐Tissue Antigen‐Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2026},
  doi = {10.1002/adma.202520594}
}
Kostenlos starten →